ArriVent BioPharma, Inc. (NASDAQ: AVBP) is a Healthcare company (Biotechnology) with a market capitalization of $553M. The Maz Rating grades it against the other companies in its sector.
ArriVent BioPharma, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $10.69, ArriVent BioPharma, Inc. trades at 110.9x sales and 1.3x book value. Over the last twelve months it generated about $5M of revenue and a net loss of $189M. It runs an operating margin of -3620.0% and a net margin of -3381.4%. It shows return on equity of -48.6%, return on invested capital of -46.0% and a free cash flow yield of -28.1%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 17.64. Over the past 52 weeks the share price ranged from $10.49 to $35.83, with a beta of 1.35.
ArriVent BioPharma, Inc. does not currently pay a dividend.
9 Wall Street analyst ratings cover the stock: 9 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.